# US 2025/0042857 A1 · SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0042857 A1
- Document ID: US20250042857A1
- Status: Published application
- Kind: A1
- Application number: 18/695,940
- Filed: 2022-09-28
- Published: 2025-02-06
- Earliest claimed: 2021-09-29
- Assignees: Haihe Biopharma Co., Ltd.
- Applicants: Haihe Biopharma Co., Ltd.
- Inventors: Dongsheng LI; Shanyun GAO; Cailu LIU; Yalei CAI; Maozhi YANG; Wangyang TU; Bing YU; Qing XIE; Yixiang ZHANG; Leping LI
- Web page: https://patentgrep.com/patent/US20250042857A1

## CPC

- C07D 215/44: with aryl radicals attached to said nitrogen atoms
- C07D 487/04: Ortho-condensed systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an SOS1 inhibitor with a pyrido-fused-six-membered ring structure, a preparation method therefor, and use thereof. The SOS1 inhibitor has the structural formula shown in formula (I) and an inhibitory activity on SOS1, and can be used to treat head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.

## Claims

### Claim 1

A compound of formula (I), and an enantiomer, a diastereoisomer, a racemate, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof,
wherein,
ring A is C6-10 aryl, 5-10 membered heteroaryl, or 4-10 membered saturated or unsaturated heterocyclyl;
m(R3) represents m identical or different R3 substituents at any position of ring A;
m is 0-5; preferably, m is 1, 2, or 3; and more preferably, m is 1 or 2;
each R3 substituent is independently selected from: hydrogen, unsubstituted or substituted C1-4 alkyl, unsubstituted or substituted C1-4 alkoxy, unsubstituted or substituted C2-4 alkynyl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-6 membered saturated or unsaturated heterocyclyl, halogen, cyano, amino, and a divalent substituent ═O; the substitution refers to being substituted by one or more substituents selected from halogen, hydroxy, cyano, and amino; and when ring A is C6-10 aryl or 5-10 membered heteroaryl, R3 is not a divalent substituent ═O;
R0 is hydrogen, halogen, C1-4 alkyl, cyano, or cyclopropyl;
R1 is hydrogen, halogen, unsubstituted or substituted C1-6 alkyl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted C1-6 alkoxy, —CN, —COOH, —CONH2, —CONH—C1-6 alkyl, amino, or —NH—C1-6 alkyl;
R2 is hydrogen, unsubstituted or substituted C1-6 alkyl, or unsubstituted or substituted C3-6 cycloalkyl;
Q1 is N, NR4, —C(O)—, or CR4, Q2 is N, NR8, —C(O)—, or CR8, Q3 is N, NR6, —C(O)—, or CR6, Q4 is N or CH; at most two N atoms are contained in Q1, Q2, Q3, and Q4; and a ring where Q1, Q2, Q3, and Q4 located and a fused ring thereof both remain aromaticity;
R4 is selected from hydrogen, unsubstituted or substituted C1-4 alkyl, unsubstituted or substituted C1-4 alkoxy, unsubstituted or substituted C2-4 alkynyl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-6 membered saturated or unsaturated heterocyclyl, halogen, cyano, and amino;
R5 and R6 are each independently hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-10 membered heteroarylo-fused 4-10 membered heterocyclyl, halogen, —CN, —COOH, —OR7, —NH—R7, —CONH—R7, —NHCO—R7, —SO2—R7, or —SO2NH—R7;
R7 is selected from hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, and unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl; and
the substitution in R1, R2, R4, R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, hydroxy-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, cyano-substituted C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)O—R8, —C(O)—CH2—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C1-10 alkoxy, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: unsubstituted or halogenated C1-6 alkyl, unsubstituted or halogenated C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, and —NH—C1-6 alkyl,
for example, the substitution in R1, R2, R4, R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, and carboxy.

### Claim 2 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein R2 is methyl or ethyl.

### Claim 3 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein ring A is phenyl.

### Claim 4 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein m is 1 or 2; and
each R3 substituent is independently selected from: substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C2-4 alkynyl, substituted or unsubstituted 4-6 membered saturated or unsaturated heterocyclyl, halogen, cyano, and amino; the substitution refers to being substituted by one or more substituents selected from halogen, hydroxy, cyano, and amino.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to any one of claims 1-4,
wherein R4 is selected from hydrogen and C1-4 alkyl.

### Claim 6 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein the compound of formula (I) has the structures of formulas (I-1-1)-(I-1-7):
wherein,
ring A, R0, R1, R2, R3, R4, R5, R6, and m are as defined in claim 1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to any one of claims 1-6,
wherein R5 and R6 are each independently hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-membered heteroarylo-fused 6-membered heterocyclyl, halogen, —CN, —COOH, —OR7, —NH—R7, —CONH—R7, —NHCO—R7, —SO2—R7, or —SO2NH—R7;
R7 is selected from hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, and unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl; and
the substitution in R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, hydroxy-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, cyano-substituted C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)O—R8, —C(O)—CH2—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: unsubstituted or halogenated C1-6 alkyl, unsubstituted or halogenated C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, and —NH—C1-6 alkyl,
for example, the substitution in R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, and carboxy;
the heteroaryl in R5, R6, R7, and the group A substituent is selected from
for example selected from
the heterocyclyl in R5, R6, R7, and the group A substituent is selected from
for example, selected from
and
the 5-membered heteroarylo-fused 6-membered heterocyclyl is selected from

### Claim 8 (depends on 7)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 7,
wherein R5 is hydrogen or C1-10 alkoxy;
R6 is selected from unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-10 membered heteroarylo-fused 4-10-membered heterocyclyl, halogen, —CN, —COOH, —OR7, —NH—R7, —CONH—R7, —NHCO—R7, —SO2—R7, and —SO2NH—R7;
R7 is selected from hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted C3-6 cycloalkyl, and unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl; and
the substitution in R6 and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, hydroxy-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, cyano-substituted C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)O—R8, —C(O)—CH2—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: unsubstituted or halogenated C1-6 alkyl, unsubstituted or halogenated C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, and —NH—C1-6 alkyl,
for example, the substitution in R6 and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, and carboxy.

### Claim 9 (depends on 7)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 7,
wherein R5 and R6 are each independently unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-membered heteroarylo-fused 6-membered heterocyclyl, halogen, —CN, —COOH, —OR7, —NH—R7, —CONH—R7, —NHCO—R7, —SO2—R7, or —SO2NH—R7;
R7 is selected from hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, and unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl; and
the substitution in R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, hydroxy-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, cyano-substituted C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)O—R8, —C(O)—CH2—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: unsubstituted or halogenated C1-6 alkyl, unsubstituted or halogenated C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, and —NH—C1-6 alkyl,
the heteroaryl in R5, R6, R7, and the group A substituent is selected from
the heterocyclyl in R5, R6, R7, and the group A substituent is selected from
the 5-membered heteroarylo-fused 6-membered heterocyclyl is selected from

### Claim 10 (depends on 7)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 7,
wherein R5 and R6 are each independently unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-membered heteroarylo-fused 6-membered heterocyclyl, halogen, —CN, —COOH, —OR7, —NH—R7, —CONH—R7, —NHCO—R7, —SO2—R7, or —SO2NH—R7;
R7 is selected from hydrogen, unsubstituted or substituted C1-10 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-6 cycloalkyl, and unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl;
the substitution in R5, R6, and R7 refers to being substituted by one or more group A substituents, which include: C1-6 alkyl, C1-6 halogenated alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, carboxy, —NH—C1-6 alkyl, —NH—C3-6 cycloalkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B-substituted C3-6 cycloalkyl, unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl, —C(O)—R8, —C(O)—NH—R8, —NH—C(O)—R8, —SO2—R8, and —SO2NH—R8; R8 is selected from hydrogen, unsubstituted or group B substituent-substituted C1-10 alkyl, unsubstituted or group B substituent-substituted C6-10 aryl, unsubstituted or group B substituent-substituted 5-10 membered heteroaryl, unsubstituted or group B substituent-substituted C3-6 cycloalkyl, and unsubstituted or group B substituent-substituted 4-10 membered saturated or unsaturated heterocyclyl; and the group B substituent includes: C1-6 alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, amino, and carboxy;
the heterocyclyl in R5, R6, R7, and the group A substituent is selected from
the heteroaryl in R5, R6, R7, and the group A substituent is selected from
the 5-membered heteroarylo-fused 6-membered heterocyclyl is selected from

### Claim 11 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein the compound of formula (I) has the structure of formula (I-2) or formula (I-3), and each symbol and variable are as defined in claim 1 provided that R2 is not hydrogen:

### Claim 12 (depends on 1)

The compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 1,
wherein the compound of formula (I is selected from the following compounds:
No.
Structure
A-1
A-2
A-3
A-4
A-5
A-6
A-7
A-8
A-9
A-10
A-11
A-12
A-13
A-14
A-15
A-16
A-17
A-18
A-19
A-20
A-21
A-22
A-23
A-24
A-25
A-26
A-27
A-28
A-29
A-30
A-31
A-32
A-33
A-34
A-35
A-36
A-37
A-38
A-39
A-40
A-41
A-42
A-43
A-44
A-45
A-46
A-47
A-48
A-49
A-50
A-51
A-52
A-53
A-54
A-55
A-56
A-57
A-58
A-59
A-60
A-61
A-62
A-63
A-64
A-65
A-66
A-67
A-68
A-69
A-70
A-71
A-72
A-73
A-74
A-75
A-76
A-77
A-78
A-79
A-80
A-81
A-82
A-83
A-84
A-85
A-86
A-87
A-88
A-89
A-90
A-91
A-92
A-93
A-94
A-95
A-96
A-97
A-98
A-99
A-100
A-101
A-102
B-1
B-2
B-3
B-4
B-5
B-6
B-7
B-8
B-9
B-10
B-11
B-12
B-13
B-14
B-15
B-16
B-17
B-18
B-19
B-20
B-21
B-22
B-23
B-24
B-25
B-26
B-27
B-28
B-29
B-30
B-31
B-32
B-33
B-34
B-35
B-36
B-37
B-38
B-39
B-40
B-41
B-42
B-43
B-44
B-45
B-46
B-47
B-48
B-49
B-50
B-51
B-52
B-53
B-54
B-55
B-56
B-57
B-58
B-59
B-60
B-61
B-62
B-63
B-64
B-65
B-66
B-67
B-68
B-69
B-70
B-71
B-72
B-73
B-74
B-75
B-76
B-77
B-78
B-79
B-80
B-81
B-82
B-83
B-84
B-85
B-86
B-87
B-88
B-89
B-90
B-91
B-92
B-93
B-94
B-95
B-96
B-97
B-98
B-99
B-100
B-101
B-102
B-103
B-104
B-105
B-106
B-107
B-108
B-109
B-110
B-111
B-112
B-113
B-114
B-115
B-116
B-117
B-118
B-119
B-120
B-121
B-122
B-123
B-124
B-125
B-126
B-127
B-128
B-129
B-130
B-131
B-132
B-133
B-134
B-135
B-136
B-137
B-138
B-139
B-140
B-141
B-142
B-143
B-144
B-145
B-146
B-147
B-148
B-149
B-150
B-151
B-152
B-153
B-154
B-155
B-156
B-157
B-158
B-159
B-160
B-161
B-162
B-163
B-164
B-165
B-166
B-167
B-168
B-169
B-170
B-171
B-172
B-173
B-174
B-175
B-176
C-1
C-2
C-3
C-4
C-5
C-6
C-7
C-8
C-9
C-10
C-11
C-12
C-13
C-14
C-15
C-16
C-17
C-18
C-19
C-20
C-21
C-22
C-23
C-24
C-25
C-26
C-27
C-28
C-29
C-30
C-31
C-32
C-33
C-34
C-35
C-36
C-37
C-38
D-1
D-2
D-3
D-4
D-5
D-6
D-7
D-8
D-9
D-10
D-11
D-12
D-13

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A pharmaceutical composition, comprising
(1) a therapeutically effective amount of the compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to any one of claims 1-12 as an active ingredient; and
(2) a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

Use of the compound of formula (I), and the enantiomer, the diastereoisomer, the racemate, the prodrug, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to any one of claims 1-12, or the pharmaceutical composition according to claim 13 in the preparation of a drug for preventing and/or treating a disease associated with mutation, activity, or expression amount of SOS1.

### Claim 15 (depends on 14)

The use according to claim 14, wherein the disease associated with mutation, activity, or expression amount of SOS1 includes head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.
